Yuvezzi is a drug owned by Visus Therapeutics Inc. It is protected by 2 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 10, 2042. Details of Yuvezzi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12268662 | Formulations Comprising Carbachol And Brimonidine To Enhance Anti- Presbyopia Effects |
Nov, 2042
(16 years from now) | Active |
| US8455494 | Preparations And Methods For Ameliorating Or Reducing Presbyopia |
May, 2030
(4 years from now) | Active |
FDA has granted several exclusivities to Yuvezzi. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Yuvezzi, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Yuvezzi.
Exclusivity Information
Yuvezzi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2029. Details of Yuvezzi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 28, 2029 |
US patents provide insights into the exclusivity only within the United States, but
Yuvezzi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Yuvezzi's family patents as well as insights into
ongoing legal events
on those patents.
Yuvezzi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Yuvezzi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 10, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Yuvezzi Generics:
There are no approved generic versions for Yuvezzi as of now.
About Yuvezzi
Yuvezzi is a drug owned by Visus Therapeutics Inc. Yuvezzi uses Brimonidine Tartrate; Carbachol as an active ingredient. Yuvezzi was launched by Visus in 2026.
Approval Date:
Yuvezzi was approved by FDA for market use on 28 January, 2026.
Active Ingredient:
Yuvezzi uses Brimonidine Tartrate; Carbachol as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate; Carbachol ingredient
Dosage:
Yuvezzi is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1%;2.75% | SOLUTION/DROPS | Prescription | OPHTHALMIC |